Sugi Predict

Sugi Predict / Compounds / SCHEMBL23218382

SCHEMBL23218382

SCHEMBL23218382

CCOC(=O)Cc1ccccc1OCc1c(C(C)=O)oc2ccc(Br)cc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 1/20 0.42
▸ CA9 Q16790 1/20 0.42
▸ TSHR P16473 3/20 0.41
▸ LMNA P02545 1/20 0.41
▸ KMT2A Q03164 4/20 0.39
▸ MAPT P10636 2/20 0.39
▸ TBXAS1 P24557 1/20 0.39
▸ PLK1 P53350 1/20 0.38
▸ NPC1 O15118 2/20 0.38
▸ RAB9A P51151 2/20 0.38
▸ KDM4E B2RXH2 2/20 0.37
▸ HSD17B10 Q99714 2/20 0.37
▸ TP53 P04637 1/20 0.37
▸ KCNH2 Q12809 1/20 0.37
▸ MEN1 O00255 2/20 0.37
▸ ALDH1A1 P00352 2/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ ALOX5 P09917 2/20 0.37
▸ HPGD P15428 1/20 0.36
▸ CFD P00746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23218295 0.92 TSHR (0.41) CA12CA9TSHRLMNAKMT2A
SCHEMBL29852813 0.92 TSHR (0.49) TSHRLMNAKMT2AMAPTTBXAS1
SCHEMBL29592706 0.92 TSHR (0.41) CA12CA9TSHRLMNAKMT2A
SCHEMBL23219253 0.92 MAPT (0.45) CA12CA9TSHRLMNAKMT2A
SCHEMBL29852615 0.92 MAPT (0.45) CA12CA9TSHRLMNAKMT2A
SCHEMBL23218747 0.92 TSHR (0.49) TSHRLMNAKMT2AMAPTTBXAS1
SCHEMBL29853250 0.89 TBXAS1 (0.41) CA12CA9TSHRLMNAKMT2A
SCHEMBL23219259 0.89 TBXAS1 (0.41) CA12CA9TSHRLMNAKMT2A
SCHEMBL23218650 0.88 TSHR (0.42) CA12CA9TSHRLMNAKMT2A
SCHEMBL29852865 0.88 TSHR (0.42) CA12CA9TSHRLMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 — — US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 — — US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 — — EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 — — CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 — — WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB CA12 1610/4885CA9 862/4885TSHR 1199/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB CA12 4035/4885CA9 2568/4885TSHR 3148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.